Novo Nordisk's Ozempic successor disappointed Wall Street again
Novo Nordisk (NVO) released clinical trial results for its potential Ozempic successor on Monday, disappointing Wall Street ...
Novo Nordisk shares fall on weight-loss drug trial
Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest ...
Seeking Alpha13d
Novo Nordisk: CagriSema Disappoints Again
Novo Nordisk ... dose after 68 weeks of treatment. If we compare across trials, CagriSema looks comparable to tirzepatide in efficacy and significantly better than semaglutide (Ozempic/Wegovy).
Nasdaq13d
Despite Challenges Novo Nordisk Plans to Crush GLP-1 Competitors
Novo Nordisk A/S (NYSE: NVO) has declared that its GLP-1 drugs for chronic obesity, under the brands Ozempic and Wegovy ... Novo Nordisk's own dual agonist experimental drug, CagriSema ...
Weight loss drug Mounjaro launched in India: Know price, how it works, side-effects, and if it’s more effective than Ozempic
The global weight-loss drug market is expected to reach $150 billion in the next decade. By 2026, semaglutide (the active ...
Blockbuster weight-loss drug Mounjaro comes to India: How does it work?
The popular anti-obesity drug Mounjaro has finally been launched in India. The development comes after Eli Lilly received ...
Eli Lilly launches its blockbuster weight loss drug Mounjaro in India
The drug will be priced at ₹3,500 for a 2.5 mg vial and ₹4,375 for the 5 mg vial. The injectable, to be taken once a week, ...
Weight Loss Drug Mounjaro Launched In India To Tackle Obesity: Is It More Effective Than Ozempic?
Another popular diabetes and weight-loss drug, Ozempic (semaglutide), manufactured by Novo Nordisk, has already established a ...